Insight Molecular Diagnostics (IMDX) Equity Ratio (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Equity Ratio data on file, last reported at 0.26 in Q1 2026.

• Quarterly Equity Ratio fell 256.22% year-over-year to 0.26 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.26 (down 256.22% YoY) and the FY2025 annual result came in at 1.22, down 249.16% from the prior year.
• Equity Ratio grew to 0.26 in Q1 2026 per IMDX's latest filing, from 1.22 in the prior quarter.
• The five-year high for Equity Ratio was 0.5 in Q2 2023, with the low at 1.22 in Q4 2025.
• Average Equity Ratio over 5 years is 0.13, with a median of 0.27 recorded in 2023.
• Year-over-year, Equity Ratio increased 17.63% in 2023 and sank 256.22% in 2026.
• Insight Molecular Diagnostics' Equity Ratio stood at 0.34 in 2022, then retreated by 20.23% to 0.27 in 2023, then tumbled by 228.02% to 0.35 in 2024, then sank by 249.16% to 1.22 in 2025, then soared by 78.35% to 0.26 in 2026.
• Business Quant data shows IMDX's Equity Ratio at 0.26 in Q1 2026, 1.22 in Q4 2025, and 0.21 in Q3 2025.